Glioblastoma Clinical Trial — Now Enrolling
Newly diagnosed with glioblastoma (GBM)? You’re not alone, and you may have options. The STAR-GBM clinical trial (NCT07185880) is enrolling now at Mayo Clinic.
STAR-GBM is a Phase 1/2 brain cancer clinical trial evaluating MT-125, an investigational therapy for adults with newly diagnosed, IDH wild-type, MGMT-unmethylated glioblastoma (WHO grade 4), given together with standard radiotherapy. If you or a loved one was just diagnosed and is weighing treatment options or seeking a second opinion, this page explains the trial and how to ask about eligibility.
Brain Cancer Clinical Trial Enrolling Now
Newly Diagnosed Glioblastoma Treatment Study — MT-125 (NCT07185880)
STAR-GBM is a Phase 1/2 study evaluating the safety, tolerability, drug levels (pharmacokinetics), and early signs of therapeutic activity of MT-125 in adults with newly diagnosed, IDH wildtype, MGMT unmethylated glioblastoma. MT-125 will be given together with standard radiotherapy on a schedule coordinated by the study team. For many patients, this is an opportunity to access an experimental brain tumor treatment that is not yet available outside of a clinical trial.
The trial is being conducted in collaboration with investigators at the Mayo Clinic, along with additional participating centers listed on ClinicalTrials.gov. If you or a loved one has been recently diagnosed with IDH wildtype, MGMT unmethylated glioblastoma, your neuro-oncologist can review the listing and discuss eligibility with you. If you may be eligible, your physician can connect you with a study coordinator. As more information becomes available, it will be provided here.
- Phase: Phase 1/2
- Status: Open for enrollment
- Intervention: MT-125 in combination with standard radiotherapy
- Condition: Newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma (WHO grade 4)
- Eligibility: Adults 18 years or older (up to 36 participants)
- Locations: Mayo Clinic — Florida, Minnesota & Arizona
- Identifiers: NCT07185880 · NCI-2026-00742
Official trial listings — the same STAR-GBM study, listed across public registries:
Where the Glioblastoma Trial Is Enrolling — Mayo Clinic Sites
Looking for a brain tumor trial near you? The STAR-GBM trial is open for enrollment at the following Mayo Clinic locations. Study statuses change often — please contact the Cancer Center Clinical Trials Referral Office at (855) 776-0015 for the most up-to-date information on possible participation.
Mayo Clinic — Jacksonville
Principal investigator: Wendy Sherman, M.D.
Status: Open for enrollment
Contact: Cancer Center Clinical Trials Referral Office
(855) 776-0015
Mayo Clinic — Rochester
Principal investigator: Ugur Sener, M.D.
Status: Open for enrollment
Contact: Cancer Center Clinical Trials Referral Office
(855) 776-0015
Mayo Clinic — Scottsdale/Phoenix
Principal investigator: Shannon Fortin Ensign, M.D., Ph.D.
Status: Open for enrollment
Contact: Cancer Center Clinical Trials Referral Office
(855) 776-0015
Just Diagnosed With Glioblastoma? What Are My Options?
A glioblastoma diagnosis is overwhelming for patients and caregivers alike. Standard treatment usually begins with surgery when feasible, followed by radiation and the chemotherapy drug temozolomide. Many families also ask their care team about clinical trials and second opinions to understand every available path forward.
If you are exploring options after a newly diagnosed GBM, a clinical trial like STAR-GBM may be worth discussing with your neuro-oncologist. Trials can provide access to investigational therapies such as MT-125 alongside standard care. Participation is always voluntary, eligibility is confirmed through screening, and your care team can help you weigh whether a trial is right for your situation. We encourage every patient and caregiver to seek a second opinion and to ask questions until they feel confident in their treatment plan.
About Glioblastoma (IDH Wild-Type, MGMT-Unmethylated)
Glioblastoma (GBM) is an extremely aggressive WHO grade 4 brain tumor in adults. The IDH wild-type, MGMT-unmethylated subtype is associated with a more limited response to standard temozolomide chemotherapy, which is one reason new approaches are being studied. Standard care often includes surgery when feasible, followed by radiation and temozolomide. The STAR-GBM trial is being conducted in collaboration with investigators at the Mayo Clinic, along with additional participating centers.
If you or a loved one has been recently diagnosed with IDH wildtype, MGMT unmethylated glioblastoma, your neuro-oncologist can review the listing and discuss eligibility with you. If you may be eligible, your physician can connect you with a study coordinator.
National Brain Tumor Society
Personalized support and education. Because every brain and CNS tumor diagnosis is unique, your care should be, too. NBTS provides easy-to-understand resources and one-on-one support to help you and your family navigate this journey. We encourage you to partner closely with your healthcare team to explore your options and choose the treatment path that is right for you.
Safety & Privacy
Patient safety and privacy are a top priority. Our studies follow FDA-authorized protocols with close monitoring for side effects, and personal health information is protected in accordance with applicable laws and site policies. Participation is voluntary, and you may withdraw at any time after speaking with your care team. If you or a loved one is not eligible for a clinical trial, you can learn more about potential pathways to access investigational treatment through our Expanded Access program.
For Physicians: Refer a Patient to the STAR-GBM Trial
Neuro-oncologists and referring physicians can direct appropriate patients to this neuro-oncology clinical trial. STAR-GBM is evaluating MT-125 as adjuvant therapy in combination with standard radiotherapy for post-resection, newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma (WHO grade 4) — a population with limited standard-of-care alternatives. To refer a patient or confirm current site status, contact the Cancer Center Clinical Trials Referral Office at (855) 776-0015, review the registry listings below, or reach Myosin Therapeutics directly through the form on this page.
Glioblastoma Clinical Trial — Frequently Asked Questions
Is there a clinical trial for newly diagnosed glioblastoma?
Yes. The STAR-GBM Phase 1/2 clinical trial (NCT07185880) is enrolling adults with newly diagnosed, IDH wild-type, MGMT-unmethylated glioblastoma, evaluating the investigational therapy MT-125 in combination with standard radiotherapy at Mayo Clinic sites in Florida, Minnesota, and Arizona.
What is MT-125?
MT-125 is an investigational therapy designed to block the myosin motor proteins that cancer cells use to move and divide. It is given together with standard radiotherapy because it is also designed to help radiotherapy work better. This is the first time MT-125 is being studied in humans, so its use is considered investigational.
Who is eligible for the GBM clinical trial?
The study is enrolling adults 18 years or older with newly diagnosed, histologically and/or molecularly confirmed IDH wild-type, MGMT-unmethylated glioblastoma (WHO grade 4). Up to 36 participants will be enrolled. Final eligibility is determined by the study team after screening tests.
Where is the glioblastoma clinical trial enrolling?
The trial is open for enrollment at Mayo Clinic in Jacksonville, Florida; Rochester, Minnesota; and Scottsdale/Phoenix, Arizona. You can reach the Cancer Center Clinical Trials Referral Office at (855) 776-0015 for the most up-to-date information.
How can a physician refer a patient to the STAR-GBM trial?
Review the official listings on ClinicalTrials.gov (NCT07185880), Mayo Clinic, and the National Cancer Institute (NCI-2026-00742), or contact the Cancer Center Clinical Trials Referral Office at (855) 776-0015. Physicians who would like to speak with Myosin Therapeutics can also contact us through the form below.
Support Our Research
Every contribution, large or small, helps accelerate first-in-class therapies targeting molecular nanomotors in cancer and neurological disease.